[{"id":"74a598bd-7a75-4999-b0f5-a6eb7255e5da","acronym":"NATASHA","url":"https://clinicaltrials.gov/study/NCT05325632","created_at":"2022-04-13T11:55:02.708Z","updated_at":"2025-02-25T13:54:21.396Z","phase":"Phase 2","brief_title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab \u0026 Pertuzumab","source_id_and_acronym":"NCT05325632 - NATASHA","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/28/2021","start_date":" 10/28/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-12-24"}]